Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Change in Cash: 2023-2025

Historic Change in Cash for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$7.0 million.

  • Mereo BioPharma Group's Change in Cash rose 13.61% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.7 million, marking a year-over-year decrease of 292.82%. This contributed to the annual value of $12.4 million for FY2024, which is 215.05% up from last year.
  • As of Q3 2025, Mereo BioPharma Group's Change in Cash stood at -$7.0 million, which was up 9.97% from -$7.8 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Change in Cash ranged from a high of $38.9 million in Q2 2024 and a low of -$9.7 million during Q4 2024.
  • For the 3-year period, Mereo BioPharma Group's Change in Cash averaged around -$1.9 million, with its median value being -$7.8 million (2025).
  • Within the past 5 years, the most significant YoY rise in Mereo BioPharma Group's Change in Cash was 605.76% (2024), while the steepest drop was 169.34% (2024).
  • Quarterly analysis of 3 years shows Mereo BioPharma Group's Change in Cash stood at -$5.1 million in 2023, then tumbled by 89.76% to -$9.7 million in 2024, then climbed by 13.61% to -$7.0 million in 2025.
  • Its Change in Cash was -$7.0 million in Q3 2025, compared to -$7.8 million in Q2 2025 and -$8.2 million in Q1 2025.